425: Akoya Biosciences Secures $30 Million Convertible Note Financing from Quanterix Amid Merger Plans

Akoya Biosciences enters into a securities purchase agreement with Quanterix for up to $30 million in convertible notes to support its financial obligations pending a potential merger.

Summary

• Akoya Biosciences has entered into a securities purchase agreement with Quanterix Corporation, dated April 2, 2025, for convertible promissory notes up to $30 million.
• Akoya can draw on these notes between May 15, 2025, and the earlier of the merger closing date or July 9, 2025, which may extend to January 9, 2026, if the merger termination date is extended.
• The convertible notes will mature 91 days after the earlier of November 1, 2027, or the date Akoya's existing loan agreement is repaid in full.
• Interest on the notes will be based on the SOFR interest rate plus an applicable margin and paid monthly.
• Quanterix has the option to convert the notes into Akoya common stock if the merger agreement is terminated, subject to a conversion price based on the merger agreement's exchange ratio and Quanterix's VWAP.
• Conversion is capped to prevent Quanterix from holding more than 19.99% of Akoya's common stock without stockholder approval.
• Akoya is required to file a registration statement for the resale of shares issued upon conversion by August 13, 2025.
• The convertible notes will be subordinate to Akoya's existing loan agreement with MidCap Financial Trust, as per a subordination agreement.
• The agreement includes customary representations, warranties, and operating covenants for Akoya until the merger's closing.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The financing provides Akoya with necessary capital, but the terms and conditions, including potential dilution and dependence on the merger's outcome, temper the overall outlook.

Positives

• Akoya gains access to up to $30 million in financing to support its operations.
• The financing is structured as convertible notes, potentially reducing Akoya's debt burden if converted to equity.
• The agreement provides flexibility in drawing funds, contingent on the merger timeline.
• The interest rate is tied to SOFR, a widely used benchmark rate.
• The subordination agreement allows Akoya to maintain its existing financing arrangements.

Negatives

• The convertible notes will increase Akoya's debt unless converted into equity.
• The conversion option could dilute existing Akoya shareholders.
• The 19.99% conversion cap may require Akoya to seek stockholder approval.
• The notes are subordinate to existing debt, potentially increasing risk for Quanterix.
• Akoya is subject to operating covenants until the merger closes.

Risks

• The merger with Quanterix may not be completed, leaving Akoya with additional debt.
• Akoya may not be able to repay the convertible notes if the merger does not proceed and conversion is not feasible.
• Changes in SOFR could impact the interest expense on the convertible notes.
• The value of Akoya's common stock could decline, reducing the attractiveness of conversion for Quanterix.
• Akoya may face challenges in obtaining stockholder approval for conversion if required.

Future Outlook

The financing is intended to support Akoya's financial obligations pending the completion of the proposed merger with Quanterix. The terms of the convertible notes are contingent on the merger's progress and potential termination.

Industry Context

This announcement reflects a strategic financial maneuver within the biotechnology sector, where companies often seek funding to support ongoing operations and strategic initiatives like mergers and acquisitions. The convertible note structure is a common tool used to bridge financing gaps while offering potential upside to the investor through equity conversion.

Comparison to Industry Standards

• Convertible note financing is a common practice in the biotech industry, particularly for companies undergoing mergers or acquisitions.
• Comparable companies like NanoString Technologies have also utilized convertible notes to secure funding.
• The interest rate based on SOFR plus a margin is typical for this type of financing.
• The conversion cap of 19.99% is a standard provision to avoid triggering stockholder approval requirements.
• The requirement to file a registration statement for resale is also a common practice to ensure liquidity for the investor.

Related Party Transactions

• The securities purchase agreement between Akoya Biosciences and Quanterix Corporation constitutes a related party transaction due to the existing merger agreement between the two companies.

Stakeholder Impact

• Shareholders may experience dilution if the convertible notes are converted into equity.
• Employees benefit from the company's increased financial stability.
• Customers and suppliers can expect continued operations and service.
• Creditors are protected by the subordination agreement.

Next Steps

• Akoya will draw on the convertible notes as needed, contingent on the merger timeline.
• Akoya will file a registration statement for the resale of shares issued upon conversion by August 13, 2025.
• Akoya may seek stockholder approval for conversion if required.
• Quanterix will monitor the progress of the merger and the performance of Akoya.

Key Dates

Keywords

Akoya Biosciences, Quanterix Corporation, convertible notes, merger agreement, financing, securities purchase agreement, SOFR, stockholder approval, registration rights, subordination agreement